Ceftaroline is a new antibacterial agent that is active against the major bacterial pathogens found in acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. The 2010 Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program in the United States collected a total of 8434 bacterial isolates from 65 US medical centers across 9 US regions. The isolates were cultured and tested for susceptibility to ceftaroline and comparator agents by reference minimum inhibitory concentration (MIC) methods. An analysis by US Census Bureau region demonstrated that Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA), and coagulase-negative staphylococci (CoNS), including methicillin-resistant CoNS, were particularly susceptible to ceftaroline (MIC 90 , 1 and 0.5 µg/mL respectively). The MRSA rate was 50.0% overall, which varied from a low of 44.6% in the South Atlantic region to a high of 53.1% in the Mountain region. Susceptibility among MRSA for ceftaroline ranged from 96.7% in the West South Central region to 100% in the West North Central region. All MRSA isolates were inhibited at a ceftaroline MIC of ≤2 μg/mL, and 98.4% were inhibited at a ceftaroline MIC of ≤1 μg/mL. In general, regional differences in activity among staphylococci, streptococci, Haemophilus spp., and Moraxella catarrhalis were minimal due to the high potency of ceftaroline. Greater differences in activity were observed among the Enterobacteriaceae due to the greater diversity of organism types and resistance mechanisms, including those producing extended-spectrum β-lactamase enzymes.
possessing broad-spectrum antimicrobial activity [28] . Its bioactive form, ceftaroline, is rapidly released in vivo upon hydrolysis of the phosphonate group. Ceftaroline fosamil was recently approved by the US Food and Drug Administration for treatment of ABSSSIs and CABP [29] .
The Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program provides contemporary and longitudinal data covering the activity of ceftaroline and comparators for relevant pathogens. In this report of the US AWARE 2010 program, an analysis by US Census Bureau regions of the activity of ceftaroline and comparator agents for key pathogens is presented.
MATERIALS AND METHODS

Organism Collection
During January through December of 2010, 65 medical centers distributed over the 9 US Census regions (5-10 medical centers per region) ( Table 1) contributed consecutively collected clinical isolates (1 strain per patient infection episode). Isolates were from various anatomic sites of infection to include respiratory tract, skin and skin structure, bloodstream, urinary tract, and other infections. Each site was requested to target 30 S. aureus, 8 coagulase-negative staphylococci (CoNS), 20 β-haemolytic streptococci, 20 S. pneumoniae, 8 viridans group streptococci, 3 Enterococcus faecalis, 10 Escherichia coli, 10 K. pneumoniae, 5 Klebsiella oxytoca, 3 Morganella morganii, 10 H. influenzae, 3 Haemophilus parainfluenzae, and 3 M. catarrhalis. Isolates were sent to JMI Laboratories (North Liberty, Iowa) for reference susceptibility testing [30] [31] [32] .
Susceptibility Testing
Isolates were tested for susceptibility to ceftaroline and multiple comparator agents by reference broth microdilution methods as described by the Clinical and Laboratory Standards Institute (CLSI) M07-A9 [30] . The CLSI interpretations were based on M100-S21 and M45-A2 breakpoints [31, 32] . Ceftaroline and tigecycline breakpoints in the product package insert were applied [29, 33] . Streptococci were tested in Mueller-Hinton broth supplemented with 3%-5% lysed horse blood, and Haemophilus spp. were tested in Haemophilus test media. Staphylococcus aureus, E. faecalis, and Enterobacteriaceae isolates were tested in cation-adjusted Mueller-Hinton broth. The quality control strains S. aureus ATCC 29213, S. pneumoniae ATCC 49619, and H. influenzae ATCC 49247 and 49766 were tested concurrently. The ESBL phenotype was defined as a minimum inhibitory concentration (MIC) ≥2 µg/ mL for ceftazidime or ceftriaxone or aztreonam [31] . 
RESULTS
Numbers of Target Organisms by Census Region and Overall
There were 8434 total isolates collected. These organisms were from documented infections, including 3055 (36.2%) from bloodstream infections (bacteremia), 2282 (27.1%) from respiratory tract infections (including CABP), 1965 (23.3%) from ABSSSIs, 665 (7.9%) from urinary tract infections, and 467 (5.5%) from other miscellaneous infection sites. The numbers of isolates, by Census region and overall, of each species/organism group tested are listed in Table 1 . The East North Central region provided the greatest number of organisms at 1396 from 10 sites, whereas the Mountain region had the fewest (598 from 5 sites). The largest number of organisms collected were S. aureus (2146), which ranged from162 in the Mountain region to 318 in the East North Central region. This was followed by 1201 β-haemolytic streptococci (range, 86-210) and 1200 S. pneumoniae (range, 79-207). Haemophilus parainfluenzae (68) and M. morganii (116) were the least frequently collected organisms.
In Vitro Activity of Ceftaroline and Comparator Agents for Key Groups and Subsets of Organisms
The in vitro activity of ceftaroline in comparison with select antimicrobial agents tested against isolates from each of the US Census regions is summarized in Tables 2-4 .
In Vitro Activity Against S. aureus
The MRSA rate was 50.0% overall and varied from a low of 44.6% in the South Atlantic region to a high of 53.1% in the Mountain region. Only two regions, the South Atlantic (44.6%) and Pacific (48.6%), had MRSA rates <50.0%. Staphylococcus aureus was very susceptible to ceftaroline (MIC 90 , 1 μg/mL; data not shown) overall. When tested against methicillin-susceptible S. aureus (MSSA), ceftaroline was >16-fold more active (MIC 90, 0.25 μg/mL) than ceftriaxone (MIC 90 , 4 μg/mL) and 4-fold more active than linezolid (1 μg/mL; data not shown). Ceftaroline and ceftriaxone MIC 90 values for MSSA (0.25 μg/mL and 4 μg/mL, respectively) were identical in all 9 Census regions ( Table 2) . Linezolid (100.0% susceptible) exhibited MIC 90 values for MSSA that were also 1 μg/mL in 6 of the Census regions but were 2 μg/mL in the West North Central, East South Central, and the Mountain regions. Tigecycline and vancomycin both exhibited 100.0% susceptibility with MIC 90 values ranging 0.12-0.25 μg/mL and 1 μg/ mL, respectively. Macrolide resistance was elevated in MSSA ( (Table 2 ). All MRSA isolates were inhibited at a ceftaroline MIC of ≤2 µg/mL (data not shown). Although ceftaroline MIC 90 values in each region were higher (4-fold) among MRSA than among MSSA (0.25 μg/mL compared with 1 µg/mL), its activity was considerably greater than other cephalosporins tested against MRSA. Furthermore, ceftaroline was slightly more potent overall than linezolid (MIC 50 and MIC 90 , 1 μg/mL) and vancomycin (MIC 50 and MIC 90 , 1 μg/mL) (data not shown). In contrast, ceftaroline was less active than tigecycline (MIC 90 ranging 0.12-0.25 μg/mL) when tested against MRSA strains ( Table 2 ). Methicillin-resistant S. aureus strains exhibited high rates of resistance to erythromycin, ranging from 83.6% in the East South Central region to 91.9% in the Mountain region. High rates of levofloxacin resistance were noted, ranging from 49.1% in the East South Central region to 84.9% in the Mountain region (data not shown).
In Vitro Activity Against β-Haemolytic Streptococci
Ceftaroline and other β-lactams were very potent against β-haemolytic streptococci, with the highest ceftaroline MIC value at 0.12 μg/mL (data not shown). Group A streptococci had MIC 90 values of ≤0.008 μg/mL in 8 regions and 0.015 μg/mL in the East North Central region for ceftaroline. The MIC 90 values in each of the 9 regions for ceftriaxone and for penicillin were at ≤0.06 and ≤0.03 μg/mL, respectively. Erythromycin regional MIC 90 values ranged ≤0.25->4 μg/mL, with susceptibility ranging 83.5%-92.1%. Clindamycin regional MIC 90 values were ≤0.25 μg/mL, with susceptibility ranging 92.2%-97.9%. Levofloxacin MIC 90 values ranged 1-2 μg/mL, with susceptibility ranging 97.8%-100.0%. Linezolid and vancomycin MIC 90 values were at 1 and 0.5 μg/mL, respectively, with 100.0% susceptibility for both group A and group B streptococci. Group B streptococci had MIC 90 values that were slightly higher for ceftaroline (0.015 μg/mL in 5 regions; 0.03 μg/mL in 4 regions), ceftriaxone (0.12 μg/mL, all regions), and penicillin (0.06 μg/mL, all regions). Erythromycin and clindamycin MIC 90 values were >4 and >2 μg/mL, respectively. The levofloxacin MIC 90 was 1 μg/mL in each Among non-ESBL phenotype strains of E. coli, regional MIC 50 values ranged 0.06-0.12 μg/mL, and susceptibility ranged from 82.1% in the West South Central region to 100% in New England, the Pacific, and East South Central regions (Table 3) . Eight of the 9 regions had susceptibility for non-ESBL phenotype E. coli >90% ( (Table 3) . Susceptibility to ceftaroline >95% in each of the 9 regions (Table 3 ). In contrast, the majority of ESBL phenotype strains showed elevated ceftaroline MIC values (MIC 50 and MIC 90 , >32 μg/mL; data not shown) and high resistance rates to other third-and fourth-generation cephalosporins (data not shown). Klebsiella pneumoniae and K. oxytoca exhibited similar susceptibility to ceftaroline (data not shown). Among non-ESBL strains, MIC 50 results were 0.06 µg/mL and 0.25 µg/mL and MIC 90 results were 0.12 µg/mL and 0.25 µg/mL for K. pneumoniae and K. oxytoca, respectively (data not shown). Decreased susceptibility in Klebsiella spp. to meropenem (MIC, ≥2 µg/mL) ranged from 0% in the Mountain and Pacific regions to 10.1% in the Mid-Atlantic region (Table 3 ). Ceftaroline showed variable activity against M. morganii, with MIC 50 values ranging 0.06-0.12 μg/mL and susceptibility rates ranging from 58.3% in the Pacific region to 81.3% in the South Atlantic region (Table 3) . Overall, 71.6% of strains were inhibited at ≤0.5 µg/mL of ceftaroline, and 81.0% of strains were susceptible to ceftazidime (data not shown). Ceftazidime regional MIC 50 values were 0.12-0.25 μg/mL, with susceptibility ranging 75.0%-87.5%. Levofloxacin susceptibility ranged 69.2%-100.0%, and gentamicin susceptibility ranged 61.5%-100.0%. Meropenem susceptibility was 100.0% for all regions, and piperacillin/ tazobactam susceptibility ranged 90.9%-100.0%.
In Vitro Activity Against the Fastidious Respiratory Tract Pathogens
A total of 1200 pneumococcal isolates were evaluated ( Table 1 ). The number of isolates ranged from 79 in the East Table 3 continued. South Central region (6 sites) to 207 in the East North Central (10 sites). The in vitro activity of ceftaroline and other β-lactams varied according to the susceptibility to penicillin.
The MIC values of β-lactams increased with penicillin MIC. However, ceftaroline was the most potent of all β-lactams tested, with regional MIC 90 values ranging 0.06-0.25 μg/mL (Table 4 values were 0.25 μg/mL in 7 regions and 0.5 μg/mL in the East North Central region, and the MIC range was 0.06-0.12 μg/mL for 9 isolates in the Mountain region. All penicillin-intermediate strains were susceptible to ceftaroline in each of the 9 regions; for penicillinresistant strains, ceftaroline susceptibility ranged from 88.9% in the East North Central region to 100.0% in the East South Central region (data not shown). The highest ceftaroline MIC value observed was 0.5 μg/mL. Ceftriaxone, amoxicillin/clavulanic acid, vancomycin, linezolid, tigecycline, and levofloxacin all exhibited high levels of susceptibility (>98%) to penicillinintermediate strains. Against penicillin-resistant (MIC, ≥2 μg/ mL) pneumococci, ceftaroline regional MIC 90 values (MIC 90 , 0.25-0.5 μg/mL) were 8-16-fold more active than ceftriaxone (MIC 90 , 2-8 μg/mL) and 32-64-fold more potent than cefuroxime and amoxicillin/clavulanic acid (MIC 90 , 8->8 μg/mL; data not shown). Regional MIC 90 values for erythromycin were all >8 μg/mL, with susceptibility ranging 0.0%-17.2%. Clindamycin MIC 90 values were all >1 μg/mL, with susceptibility ranging 27.3%-55.2%. Regional levofloxacin MIC 90 values were 1 μg/mL, with susceptibility ranging 88.9%-100.0%. Trimethoprim-sulfamethoxazole (MIC 90 , >4) susceptibility ranged 5.3%-33.3%. Tetracycline regional MIC 90 values were >8 μg/mL, with susceptibility ranging 18.5%-47.4%. Ceftaroline was highly active against H. influenzae, with MIC 90 values ranging 0.015-0.03 μg/mL across the 9 Census regions (Table 4) . Nearly all (99.7%) strains were inhibited at a ceftaroline MIC of ≤0.25 μg/mL. There was only 1 isolate with a ceftaroline MIC value of 0.5 μg/mL (East North Central region; data not shown). Ceftriaxone and cefuroxime were also highly active. Regional ceftriaxone MIC 90 values were ≤0.06 μg/mL (100.0% susceptible). Regional cefuroxime MIC 90 values were 2 μg/mL, with susceptibility ranging 97.0%-100.0%. All isolates were susceptible to levofloxacin (regional MIC 90 , ≤0.5 μg/mL) and amoxicillin/clavulanic acid (regional MIC 90 , ≤1-2 μg/mL). (Table 4) . Moraxella catarrhalis was susceptible (100.0%) to ceftriaxone, amoxicillin/clavulanic acid, tetracycline, and levofloxacin. Trimethoprim-sulfamethoxazole susceptibility ranged 84.6%-100.0%, and cefuroxime susceptiblity was 100.0% in each region except the South Atlantic (95.2%).
DISCUSSION
Bacterial resistance to antimicrobial agents is a serious public health problem. Numerous efforts have been undertaken by government and professional societies to address this issue. In 2004, the Infectious Diseases Society of America (IDSA) launched the Bad Bugs Need Drugs campaign as part of an effort to combat bacterial resistance [1] . In that effort, the IDSA identified 7 key pathogens in which development of resistance has become a major problem (ESKAPE pathogens; Enterococcus faecium, Staphylococcus aureus, Klebsiella spp., Acinetobacter spp., Pseudomonas spp., and Enterobacter spp.) and stated that there was an immediate need for new agents to treat these organisms. Further, in 2010, IDSA launched their 10 × '20 initiative in an effort to encourage the development of 10 new antimicrobials by 2020 [34] as one of the approaches to assist in controlling emerging untreatable pathogens. Methicillin-resistant S. aureus, listed among the ESKAPE pathogens, has been increasing in prevalence, causing increased morbidity and mortality [5, 6, [8] [9] [10] . It is an important pathogen in a variety of infections, including ABSSSIs [18] [19] [20] [21] [22] . The incidence of MRSA has increased to the extent that it may exceed one-half of the S. aureus strains in certain infections and geographies [18] .
Although not an ESKAPE pathogen, the emergence of MDR S. pneumoniae has also caused great concern. S. pneumoniae is the major bacterial pathogen in CABP [24] [25] [26] . Increasing rates of resistance to macrolides, tetracyclines, and penicillins/ cephalosporins have limited the therapeutic options available for this respiratory tract pathogen [24] [25] [26] .
In the 2010 US AWARE Program, ceftaroline was demonstrated to be the most potent β-lactam agent tested against staphylococci. It exhibited consistent activity across the United States, as evidenced by susceptibility rates of 100% for MSSA and rates ranging 96.7%-100% for MRSA across all 9 Census Bureau regions. Ceftaroline also showed consistent and potent activity against CoNS. For both S. aureus and CoNS, the MIC values were 2-4-fold higher for methicillin-resistant than for methicillin-susceptible isolates. Other non-β-lactam agents that demonstrated potent activity against staphylococci included linezolid, vancomycin, and tigecycline. For the β-haemolytic streptococci, there was some variation in MIC 90 values across the regions for ceftaroline; however, MIC 90 values varied only ≤0.008-0.03 μg/ mL due to the extremely potent activity. Other β-lactam agents, as well as linezolid, tigecycline, and vancomycin, demonstrated high levels of susceptibility for the β-haemolytic streptococci. Macrolide resistance was the most common resistance observed, with limited fluoroquinolone resistance noted.
Ceftaroline demonstrated potent activity against the respiratory pathogens S. pneumoniae, Haemophilus spp., and M. catarrhalis. Against S. pneumoniae, the activity of ceftaroline and other β-lactams varied according to the susceptibility to penicillin, and ceftaroline was the most potent β-lactam tested, with the highest MIC value observed at only 0.5 μg/mL. For H. influenzae, there was only 1 isolate (MIC, 0.5 µg/mL) with a ceftaroline MIC value >0.25 µg/mL, and regional MIC 90 values for H. influenzae were ≤0.03 μg/mL. Other agents that demonstrated potent activity against the respiratory pathogens included the Gram-positive agents linezolid and vancomycin and broader-spectrum agents including fluoroquinolones, tigecycline, amoxicillin/clavulanic acid, and ceftriaxone.
Ceftaroline also demonstrated potent activity against commonly encountered Gram-negative bacteria. For Enterobacteriaceae that do not express broad-spectrum β-lactamase activity (ESBL or AmpC-derepressed), ceftaroline was generally active at the breakpoint concentration [29] . Isolates with decreased susceptibility to ceftriaxone and/or ceftazidime usually exhibited elevated ceftaroline MIC values.
The results of the 2010 US AWARE Program confirmed that ceftaroline is a promising new agent with a spectrum of activity that provides expanded coverage for key pathogens found in ABSSSIs and CABP. Regional differences in activity in the United States among staphylococci, streptococci, Haemophilus spp., and M. catarrhalis were minimal due to the extreme potency of ceftaroline. Greater differences in activity were noted among the Enterobacteriaceae due to the greater diversity of organism types and resistance mechanisms, usually mediated by β-lactamases. Continued resistance surveillance along with longitudinal analysis will provide a valuable assessment of the activity of ceftaroline as this agent is used more broadly over time. Such data will provide clinicians with up-to-date information to assist them in their therapeutic decision making.
Notes
